Gedeon Christelle sold $20K of CGC

Gedeon Christelle (See Remarks) sold 13,344 shares of Canopy Growth Corp (CGC) at $1.47 on 2026-08-24.

Original reporting
SEC EDGAR · Gedeon Christelle
Published Aug 25, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Bearish
medium confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCBearishLow
01

Why it matters

The disclosed sale is small and unlikely to affect CGC's valuation materially.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$CGCBearishMedium confidence
Context

Officer Gedeon Christelle sold 13,344 shares of Canopy Growth Corp for $19,615.68 on 2026-08-24.

Expected impact

Minor downward pressure on CGC price.

Evidence & confidence

Sale size is modest ($20K) and unlikely to move the market, but insider selling can be viewed negatively.

Market effects

Minimal impact on cannabis sector.

No significant regional effect.

Low relevance globally.

Counterpoint

Insider sale may be routine and not indicative of future performance.

Key entities

  • Canopy Growth Corp

    Canadian cannabis producer listed on NYSE (ticker CGC).

  • Gedeon Christelle

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.